WEQUAL-GLOBAL
17.11.2020 15:44:08 CET | Business Wire | Press release
Twenty-four female executives of leading EMEA companies have been identified as having the leadership traits for top level C-suite positions. The WeQual Awards (www.wequal.com/awards ) identify already successful senior women who are one level below C-suite, and are aimed at tackling the slow progress in appointing women to executive roles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005907/en/
A quarter of the winners of previous UK and US WeQual Awards have since been promoted to the executive committees of FTSE and Fortune 500 companies.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the C-suite, so I launched WeQual to champion gender equality at the top,” says Katie Litchfield , founder and CEO of WeQual.
The EMEA finalists are from a wide range of sectors and companies, including Orange, Unilever, Schneider Electric, Bayer Consumer Health, ENGIE, KCB Group, Sodexo, Enel Group, L'Oréal, Mondi Group, Bureau Veritas, Standard Chartered, Veolia Environnement, Ericsson, Fresenius Medical Care, AkzoNobel, Ooredoo Qatar, Danone, Aryzta.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive & Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
Eight executive interviewers will hold 30-minute interviews with the three finalists in their category before each choosing a category winner: Brand Innovation, Commercial Performance, Digital Impact, Finance, Head of Region, People Excellence, Strategy Development, and Transformational Leadership.
The finalists will be announced in December 2020.
Among supporters of the awards are Ann Cairns, Executive Chair of Mastercard and Global Chair of the gender equality campaign group ‘30% Club’; Sir Ian Cheshire, Chairman of Barclays; Dame Inga Beale; and Ron Kalifa OBE of Network International. They are part of a roster of well-known C-suite executives who will now choose eight category winners.
Sir Ian Cheshire says: "These awards are among the first to target women at this level. We believe building awareness of these talented people, as well as connecting them to each other, is an important step in improving diversity at top levels of business.”
This senior group of 24 executives will become members of the WeQual Club and join the existing 72 senior FTSE and Fortune 500 female executives.
(Ends)
Notes to editors
Methodology: The eight assessment questions were developed from a research-based meta-analysis of the factors and characteristics that mark leaders as different from non-leaders (Kirkpatrick and Locke, 1991). They were designed to help the women best describe how they deliver on leadership characteristics and how they are seen by others as a leader, and indeed engage people who see them as fit to lead.
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they are deserving to be appointed to the Executive Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom